A few observations.
David Hastings resigned from Incyte (market cap $12 billion) in October 2014 "to pursue other opportunities".
A former CFO from Celgene (market cap $97 billion) took over David's place at Incyte.
A cursory look at Incyte's financials up to 2013 they have not generated a profit and had negative equity (i.e. it's liabilities exceeded its assets). Not a reflection on David but it shows he's had to navigate a company with tight finances.
Another observation is Incyte commanded a $10-12 billion market cap generating $300 million per year in gross revenue WITHOUT generating any profits or break even cash flows.
- Forums
- ASX - By Stock
- UNS
- New CFO
New CFO, page-24
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)